DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Guarneri V, Bisagni G, Frassoldati A. et al.
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with
HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole:
Final results of the PerELISA neoadjuvant study.
J Clin Oncol. 2018
36. (suppl; abstr 507)
Access:
We do not assume any responsibility for the contents of the web pages of other providers.